Category: News

BioProNET is ending – stay in touch

BioProNET was granted a no-cost extension by the BBSRC to run until the end of August 2019. We have been investigating mechanisms by which to sustain the network beyond August 2019, and in particular to hold a Science Meeting in 2020.

Due to data protection rules, we are not allowed to use our BioProNET mailing list once funding for the network has finished.

Thank you for clicking on the link in an email that was sent to you indicate that you would like to stay in touch and be kept informed of a future bioprocessing network. Your preference has been noted.

If you arrived at this page not through an email link but would like to stay in touch please contact Charlotte c.harrison-560@kent.ac.uk

6th Annual Science Meeting

The Principal Hotel, Manchester
June 3-4th 2019

Our flagship science meeting this year reflected on the science that has been developed to date through BioProNET support, and also provide a forward vision of the science that will underpin the next 10 years of bioprocessing.

10.00 Registration
The Cell Factory: Proteins are go

co-chaired by Emma Hargreaves and Mark Smales

11.00 Nicole Borth, University of Natural Resources and Life Sciences (BOKU), Vienna – CHO genome news: variation, phenotypes and control
11.30 Tobias von der Haar, University of Kent – Controlling bioprocessing parameters through efficient sequence design
11.45 Sarah Smith, University of Warwick – Exploiting electron microscopy to optimise protein and biologic expression systems
12.00 Anil Day, University of Manchester – A high-yield expression platform for manufacturing recombinant human growth factors
12.15 Jose Guterriez-Marcos, University of Warwick – Rapid production of high value biologics in plant cell cultures
12.30 Poster talks: Gizem Buldum, Imperial College London – Monitoring the effect of accessory proteins on a CHO-based cell-free protein synthesis factory

Théo Mozzanino, University of Kent – Engineering the CHO secretory pathway for enhanced secretory recombinant protein production

12.40 Douglas Browning, University of Birmingham – Playing a round with recombinant protein production: what is PAR for the course
12.55 Lunch
The Cell Factory: Nucleic acids are go    chaired by Nicole Borth
14.00 Uta Griesenbach, Imperial College London – Latest developments in cystic fibrosis gene therapy
14.30 Michael Plevin, University of York – DNA motor proteins for nanopore sequencing
14:45 Duygu Dikicioglu, University of Cambridge – Addressing challenges in pre-processing and mining bioprocess development data in biocatalyst manufacturing by machine learning
15.00 Lorna Ashton, Lancaster University – Raman spectroscopy and gene therapy
15.15 Poster talks: George Prout, Cobra Biologics – Optimisation of a scalable rAAV production process 

Zoltán Kis, Imperial College London – Techno-economic analysis of emerging vaccine platform and production technologies 

15:25 James Budge, University of Kent – Engineering of CHO cell lipid metabolism to enhance biotherapeutic protein production
15.40 Refreshment break, networking, posters
Beyond the Cell and into Manufacturing          chaired by Gary Lye
16.10 Nigel Robinson, Durham University – Protein metalation in Industrial Biotechnology: E3B BBSRC NIBB opportunities
16.40 Jon Sayers, University of Sheffield – Engineering nucleases for genetic engineering and diagnostic applications
16.55 Gary Montague, Teesside University – Improved preservation of biologics by continuous intensified lyophilisation
17.10 Hirra Hussain & Louis Darton, Universities of Manchester and Kent – The BBSRC-funded Strategic Training Awards for Research Skills (STARS): The Bioprocessing Training Programme
17.25 Mark Carver, Bio-Industry Association SIAC – Shaping the future: where next for bio-processing research?
17.55 Hotel check-in
18.20 Poster session and drinks reception
20.00 Conference dinner

Day 2 – 4thJune

New Approaches and Enabling Technologies        chaired by Paul Dalby
8.45 Paul Kellam, Kymab – Deep mining of antibody responses – picking your best therapeutic mAb or vaccine
9.15 James Winterburn, University of Manchester – Enhanced glycolipid production and separation: from bench to business with UKRI funding
9.30 Alan Goddard, Aston University – Separation of sub-micron biologicals using microfluidic devices
9.45 Mark Wass, University of Kent – In silico analysis of host cell protein impurities in antibody purification
10.00 Jim Warwicker, University of Manchester – Computational approaches to study biopharmaceutical stability and formulation
10.15 Poster talks: Cloé Legrand, University of Cambridge – MRI characterisation of a microscale parallel bioreactor 

Guido Zampieri, Teesside University – Combining machine learning and metabolic modelling as a tool for bioprocess development

10.25 David Brockwell, University of Leeds – Assessing biopharmaceutical aggregation in vivo and in vitro
10.55 Refreshment break, networking, posters
The Future Should Not Be Unexpected         chaired by Alan Dickson
11.25 Damian Marshall, Cell and Gene Therapy Catapult – Cell and gene therapy manufacture: the emerging role for AI
11.55 Ray Field, AdaptImmune – Bioprocessing for autologous T cell therapy
12.25 Poster talks: Denis Calnan, Thermo Fisher Scientific – A high resolution accurate mass multi-attribute method for critical quality attribute monitoring & new peak detection

Vera Lukashchuk, Cobra Biologics – Development of analytical package for AAV vectors: focus on qPCR 

Tim Eyes, University of Manchester – GeneORator: Smart DNA library design to accelerate the identification of improved protein variants

12.40 Peter Levison, Pall Biotech – Operating in a changing landscape: future process development strategies
13.10 Prize presentation – Colin Miles, BBSRC
13.15 Lunch and meeting close

 

BioProNET extension

We are pleased to inform you that BioProNET has been granted a no-cost extension by the BBSRC to run until the end of August 2019. There is no additional funding associated with the extension, however we will have the opportunity to use the extension period to investigate, and put in place, mechanisms by which to sustain the network beyond August 2019.

We have already been in discussion with key stakeholders in industry and academia to ensure that the continuation of such a network is required, and in response had incredible support with regard to the need to ensure such an academic-industrial UK based network continues and thrives. As we develop our plans in the next 3-4 months for a sustainable network, we hope that all within the network will support the need for such a network and provide their input and ideas regarding the sustainability of the network. Please do contact us biopronet@biopronetuk.org if you have any thoughts or would like to be involved.

In addition to developing mechanisms for a sustainable BioProNET, we plan to hold the annual science meeting this year, potentially in late July, and a further meeting in October. We will have more firm plans in a few weeks, and will keep BioProNET members updated through newsletters, our website http://biopronetuk.org and Twitter (@BioProNETUK).

Additional focussed meetings, and those in collaboration with other organisations and the new phase II NIBB, are also being investigated. The BBSRC STARS programme, that BioProNET has helped deliver for the last 2 years, will also be running again in September 2019. We will also be continuing to collect outputs and impact of BioProNET activities.

We look forward to your continued support and seeing you at a BioProNET event soon.

BioProNET members win innovator of the year

BioProNET members Ben Dolman and James Winterburn won the BBSRC 2018 Innovator of the Year in the Early Career researcher category.

Some information about their innovative work — partly funded by BioProNET — can be found on our case studies page http://biopronetuk.org/case-studies-of-biopronet-funding/
Scientific exchange visit boosts separation technologies collaboration
Collaborative development of glycolipid separation technology to reduce costs

5th Annual Science Meeting

October 10-11th 2018
British Medical Association House, Central London

Thank you to everyone who made this meeting a huge success. Photos will be shared with members once the photos are ready.

Wednesday October 10th
9.30 Registration
10.15-10.30 Welcome, achievements and what next for BioProNET
Designing more efficient cell-expression systems chaired by Mark Smales
10.30-10.55 Kerstin Otte
 University of Applied Science Biberach, Germany Identification and characterisation of intracellular production bottlenecks in CHO cells producing complex biopharmaceuticals
10.55-11.20 Colin Robinson University of Kent Development of next generation E. coli platforms for the regulated production and periplasmic targeting of biotherapeutics
11.20-11.45 Tarit Mukhopadhyay University College London Manufacturing the future at less than a $1 a dose and meeting global health needs
11.45-11.55 Andrew Peden University of Sheffield Developing a toolkit for determining the manufacturability of new therapeutics in CHO cells 
11.55-12.20 Nathan Lewis University of California San Diego, USA Engineering CHO cells with enhanced traits with multiplex genome editing

Building expression systems into optimised process chaired by Yvonne Genzel
13.25-13.50 Gary Finka GlaxoSmithKline Developing a next-generation cell line development platform through targeted automation, analytics and informatics
13.50-14.15 Sophia Hober Royal Institute of Technology, Sweden The human secretome project
14.15-14.25 Mayur Parekh Teesside University Improved preservation of biologics by continuous intensified lyophilisation
14.25-14.35 James Winterburn University of Manchester From bench to business with UKRI funding
14.35–15.00 Natalio Krasnogor Newcastle University Synthetic portabolomics: bridging the gap between the lab bench and industry to speed up the development of new biotech products

The clinic and beyond chaired by Laura Palomares
15.40-16.05 Caroline Barelle Elasmogen soloMERä Biologics: Site-specific therapeutic biologics for the treatment of inflammatory disease
16.05-16.20 Simon Saxby Leaf Expression Systems Plant produced biologics – process economics
16.20-16.30 Michael Plevin University of York Can an archaeal helicase enhance the performance of a nanopore DNA sequencer?
16.30-16.40 Pavlos Kotidis Imperial College London A mathematical model to describe CHO cell growth and monoclonal antibody glycosylation

18.00 Poster session
20.00 Conference dinner

Thursday October 11th
Upstream meets downstream – rapid process development chaired by Cleo Kontoravdi
9.00-9.25 Paul Dalby University College London Analysis and control of protein dynamics and stability: downstream to formulation
9.25-9.50 Yvonne Genzel Max Planck Institute for Dynamics of Complex Technical Systems, Germany Intensified cell-based viral vaccine processes: from continuous to perfusion and to hybrid systems
9.50-10.15 Maiken Kristiansen MedImmune Nucleic acid production for biotherapeutics
10.15-10.25 Dave Brockwell University of Leeds Investigating the effects of hydrodynamic force on the structure and biological integrity of a viral vector gene therapy product
10.25-10.35 Davide Vito University of Kent Translation engineering through the non-coding genome in CHO cells
10.35-11.00 Pernille Harris Technical University of Denmark Solution structure and self-association of pharmaceutical proteins

Molecular characterisation of process quality chaired by Alan Dickson
11.40-12.05 Mike Betenbaugh Johns Hopkins University, USA Glycoengineering of mammalian cell lines to improve product quality
12.05-12.30 Laura Palomares National Autonomous University of Mexico Challenges of bringing recombinant vaccines to the market: A case study for a influenza vaccine
12.30-12.40 Perdita Barran University of Manchester Top-down mass spectrometry methods for full characterisation of biopharmaceuticals
12.40-12.50 Rosa Morra University of Manchester Classical and non-classical secretion pathways in E. coli for periplasmic and extracellular recombinant protein production
12.50-13.15 Jonathan Bones The National Institute for Bioprocessing Research and Training, Ireland Characterisation of biopharmaceuticals using intact protein separations hyphenated to high resolution native mass spectrometry